Tuesday, October 18, 2022 2:07:35 AM
I certainly agree with all items as upcoming milestones, but based on what the company has said you have numbers 1 and 2 reversed. Perhaps if Dr. Liau's SNO presentation goes much further than prior presentation after a peer reviewed Abstract then the company will release TLD before the Journal is out if it doesn't come out prior, but otherwise TLD doesn't get issued until we have the Journal.
The only milestones I believe you could add that should make a difference in the stock price is when the company officially is notified, and notifies us that their applications for approval from the regulators have each been accepted. We know the preliminaries required by the U.K. have been accepted, anticipated timing says they ought to be considering the application by now. In the U.S. there are no similar preliminary filings, all is rolled into the BLA, no one has indicated if either the Europeans or the Canadians have any preliminary filings required. While the general feeling is that the U.K. will be first, can anyone be certain that all four regulators won't receive the applications simultaneously. I believe in the U.K. first scenario, but I also believe that all possibilities are on the table.
Gary
The only milestones I believe you could add that should make a difference in the stock price is when the company officially is notified, and notifies us that their applications for approval from the regulators have each been accepted. We know the preliminaries required by the U.K. have been accepted, anticipated timing says they ought to be considering the application by now. In the U.S. there are no similar preliminary filings, all is rolled into the BLA, no one has indicated if either the Europeans or the Canadians have any preliminary filings required. While the general feeling is that the U.K. will be first, can anyone be certain that all four regulators won't receive the applications simultaneously. I believe in the U.K. first scenario, but I also believe that all possibilities are on the table.
Gary
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
